In the specific context of pathologic decrease of bone matrix mineralization which can be found in various metabolic bone diseases such as osteomalacia, chronic kidney disease‐mineral bone disorder or hypophosphatasia, increased expression of TROP2 might act as a stimulator of MSC osteogenic differentiation in an attempt to improve the bone structure by osteoblasts.34, 35. This evidence concerns the gene TACSTD2 and hypophosphatasia.